A5100675711- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Pancreatic function and diabetes
- Hernia repair and management
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Chronic Lymphocytic Leukemia Research
- RNA Interference and Gene Delivery
- Growth Hormone and Insulin-like Growth Factors
- Gastric Cancer Management and Outcomes
- Cancer Risks and Factors
- Metabolism, Diabetes, and Cancer
- Cancer-related molecular mechanisms research
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Diabetes and associated disorders
- Adipose Tissue and Metabolism
- Ubiquitin and proteasome pathways
Chinese Academy of Medical Sciences & Peking Union Medical College
2012-2025
Northwestern University
2014-2025
Guangxi University
2025
National Institutes of Health
2006-2024
National Cancer Institute
2008-2024
Stomatological Hospital of Chongqing Medical University
2024
Chongqing Medical University
2024
University of Louisville
2010-2024
Shanxi Medical University
2006-2024
Sun Yat-sen University
2004-2024
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features the tumors. We used gene-expression profiles these lymphomas to develop a predictor survival.
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center [GCB], unclassified) according to cell origin that associated with a differential response chemotherapy targeted agents. We sought extend these findings by identifying genetic subtypes based on shared genomic abnormalities uncover therapeutic vulnerabilities tumor genetics.
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival patients diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate after treatment lymphoma is unclear.We profiled gene expression in pretreatment biopsy specimens from 181 who received CHOP 233 this disease R-CHOP. A multivariate gene-expression-based survival-predictor model derived a training...
Patients with follicular lymphoma may survive for periods of less than 1 year to more 20 years after diagnosis. We used gene-expression profiles tumor-biopsy specimens obtained at diagnosis develop a molecular predictor the length survival.Gene-expression profiling was performed on 191 biopsy from patients untreated lymphoma. Supervised methods were discover expression patterns associated survival in training set 95 specimens. A constructed these genes and validated an independent test 96...
The distinction between Burkitt's lymphoma and diffuse large-B-cell is crucial because these two types of require different treatments. We examined whether gene-expression profiling could reliably distinguish from lymphoma.Tumor-biopsy specimens 303 patients with aggressive lymphomas were profiled for gene expression also classified according to morphology, immunohistochemistry, detection the t(8;14) c-myc translocation.A classifier based on correctly identified all 25 pathologically...
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. In least curable (ABC) subtype DLBCL, survival malignant cells dependent on constitutive activation nuclear factor-kappaB (NF-kappaB) signaling pathway. normal cells, antigen receptor-induced NF-kappaB requires CARD11, a cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumorigenesis, we sequenced gene in human DLBCL tumors. We detected missense mutations 7 73 ABC biopsies...
Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast (TNBC). Integrating spatial resolution of cells with laser capture microdissection gene expression profiles, we defined distinct TIME stratification TNBC, implications current therapies including checkpoint blockade. TNBCs an immunoreactive exhibited tumoral infiltration granzyme B+CD8+ T (GzmB+CD8+ cells), a type 1 IFN signature, and elevated multiple...
Abstract On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, follows: (a) first-line mNSCLC have high PD-L1 expression (tumor proportion score [TPS] ≥50%), no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase...
Abstract On August 5, 2016, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth, NJ) for treatment of patients with recurrent or metastatic head neck squamous cell carcinoma (HNSCC) disease progression on after platinum-containing chemotherapy. Approval was based objective response rate (ORR) duration (DoR) in a cohort nonrandomized multi-cohort trial (KEYNOTE-012) that included 174 HNSCC who had...
To find an electrical conductivity (EC) in the nutrient solution used for pakchoi (Brassica campestris L. ssp. Chinensis) cultivation that optimizes plant's physiology, growth, and quality, we conducted experiment with eight EC treatments (from EC0 to EC9.6) a hydroponic production system (i.e. soilless culture) under greenhouse condition Shanghai, China. Plants biomass production, leaf photosynthesis, vegetable quality variables, tissue nitrate nitrite contents, antioxidant enzyme...
On May 29, 2020, the FDA approved atezolizumab for use in combination with bevacizumab, treatment of adult patients unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) no prior systemic treatment. The approval was based on data from Study IMbrave150, which randomly allocated (2:1) to receive either plus bevacizumab (atezolizumab-bevacizumab) sorafenib. Overall survival (OS) and independently assessed progression-free (PFS) intent-to-treat population were primary...